Christine Luxemburger

TL;DR: In this area of low malaria transmission, early diagnosis and treatment with combined artesunate and me floquine has reduced the incidence of P. falciparum malaria and halted the progression of mefloquine resistance.

TL;DR: The introduction of the artemisinin derivatives in routine treatment at this study site in mid 1994 was associated with a reduction in the subsequent incidence of falciparum malaria and may prevent the spread of multidrug resistance.

TL;DR: Children aged < 5 years of age were more likely than older children or adults to become anemic, and patients coinfected with P. vivax attenuates the anemia of falciparum malaria, presumably by modifying the severity of the infection.

TL;DR: The predisposing factors, clinical presentation, and outcome of severe malaria in a Karen community living on the western border of Thailand were studied over a period of 2 years, suggesting that P. vivax may attenuate the severity of P. falciparum malaria.

TL;DR: In a prospective study of acute uncomplicated, multidrug-resistant falciparum malaria on the western border of Thailand, the oral artemisinin derivatives were used alone in the treatment of 836 patients (artesunate 630, artemether 206), were combined with mefloquine (15-25 mg base/kg) in 2,826 patients, and me floquine alone was used in 1,303 patients as discussed by the authors.